tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Porokeratosis D017499 1 associated lipids
Lentigo D007911 1 associated lipids
Mutism D009155 1 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Orchitis D009920 1 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Meningitis, Fungal D016921 1 associated lipids
Malocclusion, Angle Class II D008312 1 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dysuria D053159 1 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Akinetic Mutism D000405 1 associated lipids
Sleep Apnea, Central D020182 1 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Priapism D011317 1 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Retrognathia D063173 1 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Poxviridae Infections D011213 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Lacerations D022125 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Tinea Capitis D014006 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Nocturia D053158 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Apraxias D001072 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Rectal Diseases D012002 1 associated lipids
Citrullinemia D020159 1 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Optic Neuritis D009902 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Lung Abscess D008169 1 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Intertrigo D007402 1 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Mite Infestations D008924 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Leukoplakia D007971 1 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Malacoplakia D008287 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Lichen Nitidus D017513 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Lymphocele D008210 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Hand Injuries D006230 1 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Myelitis D009187 1 associated lipids
IgG Deficiency D017099 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Fung JJ Tacrolimus and transplantation: a decade in review. 2004 Transplantation pmid:15201685
Busuttil RW and Lake JR Role of tacrolimus in the evolution of liver transplantation. 2004 Transplantation pmid:15201686
Gjertson DW et al. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. 1995 Transplantation pmid:8545861
Plock JA et al. Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells Prolong Graft Survival in Vascularized Composite Allotransplantation. 2015 Transplantation pmid:26102613
Bunnapradist S et al. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids. 2003 Transplantation pmid:12865780
Arns W et al. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. 2017 Transplantation pmid:28658202
Taber DJ et al. Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation. 2017 Transplantation pmid:28658199
Hashimoto T et al. Treatment with FK506 prevents rejection of rat colon allografts. 1994 Transplantation pmid:7516586
Gonwa T et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. 2003 Transplantation pmid:12829910
Andrés A et al. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration. 2009 Transplantation pmid:19898206
Larsen JL et al. Tacrolimus and sirolimus cause insulin resistance in normal sprague dawley rats. 2006 Transplantation pmid:16926589
Fisher NC et al. Chronic renal failure following liver transplantation: a retrospective analysis. 1998 Transplantation pmid:9679823
Ericzon BG et al. The effect of FK506 treatment on pancreaticoduodenal allotransplantation in the primate. 1992 Transplantation pmid:1376501
Solez K et al. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. 1998 Transplantation pmid:9884269
Yamamoto S et al. FK778 and FK506 combination therapy to control acute rejection after rat liver allotransplantation. 2004 Transplantation pmid:15591950
Tan HP et al. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. 2004 Transplantation pmid:15591960
Squifflet JP et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. 2001 Transplantation pmid:11468536
Theruvath TP et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. 2001 Transplantation pmid:11468538
Zervos XA et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. 1998 Transplantation pmid:9583863
Moreau C et al. Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient. 2006 Transplantation pmid:16477241
Shaffer D et al. Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). 1995 Transplantation pmid:7535958
Bronster DJ et al. Demyelinating sensorimotor polyneuropathy after administration of FK506. 1995 Transplantation pmid:7535959
Piao SG et al. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions. 2014 Transplantation pmid:24825522
Gujadhur A et al. CMV sinusitis in a HIV-negative renal transplant recipient. 2014 Transplantation pmid:24827770
Riegersperger M et al. Effect of conversion from ciclosporin to tacrolimus on endothelial progenitor cells in stable long-term kidney transplant recipients. 2013 Transplantation pmid:23594858
Chakrabarti P et al. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. 2000 Transplantation pmid:11003353
van Maarseveen EM et al. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study. 2013 Transplantation pmid:23250333
Gouraud A et al. Follow-up of tacrolimus breastfed babies. 2012 Transplantation pmid:22996303
Hougardy JM et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. 2011 Transplantation pmid:21192316
Neuhaus P et al. Quadruple tacrolimus-based induction therapy including azathioprine and ALG does not significantly improve outcome after liver transplantation when compared with standard induction with tacrolimus and steroids: results of a prospective, randomized trial. 2000 Transplantation pmid:10868638
Mohamed MA et al. TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. 2000 Transplantation pmid:10755567
Anil Kumar MS et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. 2005 Transplantation pmid:16210969
Ellis D et al. Renal transplantation in children managed with lymphocyte depleting agents and low-dose maintenance tacrolimus monotherapy. 2007 Transplantation pmid:17589338
Deuse T et al. Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545. 2012 Transplantation pmid:22971540
Shapiro R et al. Tacrolimus in pediatric renal transplantation. 1996 Transplantation pmid:8990356
Przepiorka D et al. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. 1996 Transplantation pmid:8990368
Ko S et al. The pharmacokinetic benefits of newly developed liposome-incorporated FK506. 1994 Transplantation pmid:7526494
Holländer GA et al. Disruption of T cell development and repertoire selection by calcineurin inhibition in vivo. 1994 Transplantation pmid:7526495
Inomata Y et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. 1996 Transplantation pmid:8600632
Gruessner RW et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. 1996 Transplantation pmid:8600635
Cezário ES et al. Gingival overgrowth in renal transplant subjects medicated with tacrolimus in the absence of calcium channel blockers. 2008 Transplantation pmid:18212628
Jordan ML et al. Tacrolimus for rescue of refractory renal allograft rejection. 1998 Transplant. Proc. pmid:9636511
Neuhaus PJ Optimised first-line FK506-based protocols in liver transplantation: experience from the University Hospital Rudolf Virchow, Berlin. 1994 Transplant. Proc. pmid:7527961
Jordan ML et al. FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. 1993 Transplant. Proc. pmid:7679827
Jusko WJ and D'Ambrosio R Monitoring FK 506 concentrations in plasma and whole blood. 1991 Transplant. Proc. pmid:1721260
Millis JM et al. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients. 1996 Transplant. Proc. pmid:8623213
Sugioka A et al. FK 506 inhibits tolerance induction in mice liver transplantation. 2005 Jan-Feb Transplant. Proc. pmid:15808576
Staschak S et al. A cost comparison of liver transplantation with FK 506 or CyA as the primary immunosuppressive agent. 1990 Transplant. Proc. pmid:1689896
Aravot D et al. A new immunosuppressive protocol for lung transplantation: early promising results. 2003 Transplant. Proc. pmid:12644072
Molleví DG et al. Late xenograft rejection: comparison between liver and heart xenografts under low-dose tacrolimus. 2002 Transplant. Proc. pmid:11959212
Cai TH et al. Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation. 1998 Transplant. Proc. pmid:9636572
Mazali FC et al. Posttransplant diabetes mellitus: incidence and risk factors. 2008 Transplant. Proc. pmid:18455010
Moriuchi H et al. Mechanisms of immunosuppressive effects of FK 506 in light of apoptosis of hepatocytes and infiltrating lymphocytes in rat allografted livers. 2000 Transplant. Proc. pmid:11120182
Oliveira DB and Chang R Report of the first 118 tacrolimus-treated patients at St George's Hospital, London. 1999 Transplant. Proc. pmid:10576047
Asano T et al. Increased tacrolimus trough levels in association with severe diarrhea, a case report. 2004 Transplant. Proc. pmid:15518758
Akselband Y et al. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. 1991 Transplant. Proc. pmid:1721292
Klintmalm GB Clinical use of FK 506 in liver transplantation. 1996 Transplant. Proc. pmid:8623484
Merli M et al. Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient. 2010 Transplant. Proc. pmid:20534292
Gerber DA et al. Immunosuppressive agents: recent developments in molecular action and clinical application. 1998 Transplant. Proc. pmid:9636637
Fan Y et al. Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta-analysis. 2009 Transplant. Proc. pmid:19545736
Xu M et al. Effect of peritransplant FTY720 alone or in combination with posttransplant FK 506 in a rat model of cardiac allotransplantation. 1997 Transplant. Proc. pmid:9365631
Spada M et al. Monitoring of intestinal myoelectrical activity after isolated small bowel transplantation in FK 506 immunosuppressed pigs. 1994 Transplant. Proc. pmid:7518141
Ziolkowski J et al. Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity. 2003 Transplant. Proc. pmid:14529923
Junge G et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. 2005 Transplant. Proc. pmid:15919434
Martinez OM et al. Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. 1995 Transplant. Proc. pmid:7533372
Ushigome H et al. Pediatric living-related renal transplantation under tacrolimus as the primary immunosuppressive agent. 2003 Transplant. Proc. pmid:12591350
Daly I et al. Mycophenolate mofetil for treatment of chronic rejection in liver allograft under tacrolimus. 2002 Transplant. Proc. pmid:12176458
Orlandi V et al. Tacrolimus-associated myositis: a case report in a renal transplant patient. 2004 Transplant. Proc. pmid:15110639
Pohanka E et al. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients. 2005 Transplant. Proc. pmid:15919490
Shapiro R et al. A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. 1995 Transplant. Proc. pmid:7533432
Whiteside TL et al. Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. 1991 Transplant. Proc. pmid:1721356
Fischereder M et al. Gynaecomastia following solid organ transplantation. 2002 Transplant. Proc. pmid:12270376
Bennett WM Renal complications after heart transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083019
Ko S et al. Predominant role of local immunosuppressive effect in enhanced efficacy of liposomal FK506 in organ transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123117
Rao AS et al. Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. 1996 Transplant. Proc. pmid:8908140
Kim YI et al. FK 506 prevents critical warm ischemia damage to the pig liver and improves hepatic microcirculation. 1994 Transplant. Proc. pmid:7520636
Winkler M et al. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. 1991 Transplant. Proc. pmid:1721389
Paul LC Overview of side effects of immunosuppressive therapy. 2001 Transplant. Proc. pmid:11377462
Rodrigo E et al. Histopathological findings according to Banff-97 classification system comparing tacrolimus versus cyclosporine. 2002 Transplant. Proc. pmid:12176550
Jordán de Luna C et al. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels. 2011 Jul-Aug Transplant. Proc. pmid:21839244
Elinav H et al. Plasma oxidizability and plasma carbonyls, markers of oxidative stress, in liver transplant patients. 2001 Transplant. Proc. pmid:11543789
Opelz G Immunosuppression with FK 506 does not improve kidney graft survival. Collaborative Transplant Study. 1999 Feb-Mar Transplant. Proc. pmid:10083513
Troppmann C et al. FK 506 versus cyclosporine A for steroid-free synergistic combination therapy with rapamycin in a discordant large animal donor xenoislet transplant model. 1997 Feb-Mar Transplant. Proc. pmid:9123585
Braun N et al. Impairment of renal function following liver transplantation. 2003 Transplant. Proc. pmid:12826191
Cooper MH et al. The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. 1991 Transplant. Proc. pmid:1721419
Yagura K et al. Pharmacokinetic characteristics of two types of liposomal FK 506. 1996 Transplant. Proc. pmid:8658708
Taber DJ et al. Drug-drug interaction between chloramphenicol and tacrolimus in a liver transplant recipient. 2000 Transplant. Proc. pmid:10812156
El-Sabrout R et al. Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients--a single center experience. 2003 Transplant. Proc. pmid:12742474
Kamar N et al. Efficacy and safety of induction therapy with rabbit antithymocyte globulins in liver transplantation for hepatitis C. 2004 Transplant. Proc. pmid:15621141
Filler G et al. One-year glomerular filtration rate predicts graft survival in pediatric renal recipients: a randomized trial of tacrolimus vs cyclosporine microemulsion. 2002 Transplant. Proc. pmid:12176634
Glanemann M et al. Mycophenolate mofetil is superior in combination with tacrolimus compared to cyclosporine for immunosuppressive therapy after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267194
Kohnle M et al. Conversion to tacrolimus in cyclosporin A treated patients with gum hyperplasia. 1998 Transplant. Proc. pmid:9723413
Alessiani M et al. Effect of perioperative donor bone marrow infusion after small bowel transplantation in swine: preliminary results. 1998 Transplant. Proc. pmid:9745496
Makowka L et al. The effect of FK-506 on hyperacute rejection in presensitized rats. 1987 Transplant. Proc. pmid:2445082
Neff GW et al. Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. 2003 Transplant. Proc. pmid:14697970
Abu-Elmagd K et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. 1991 Transplant. Proc. pmid:1721451
Mehra MR et al. Racial differences in clinical outcome using tacrolimus and mycophenolate mofetil immunosuppression in heart transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267442
Yura H et al. Development of a macromolecular prodrug of FK 506: II: In vitro study for FK 506-dextran conjugate. 1998 Transplant. Proc. pmid:9636416
Wu J et al. Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. 1991 Transplant. Proc. pmid:1703683
Lawen J et al. Sirolimus and low-dose tacrolimus with antibody induction in kidney transplantation: preliminary results of a pilot study. 2001 Nov-Dec Transplant. Proc. pmid:11750382